Login to Your Account

Kala Pharmaceuticals eyes $86.25M IPO to prepare for commercial launch

By Marie Powers
News Editor

Monday, June 26, 2017

With two phase III studies of lead compound, KPI-121 1.0 percent, in the books to treat inflammation and pain following cataract surgery, Kala Pharmaceuticals Inc. looked to the public markets to fund pre-commercialization activities for the nanoparticle-based therapy by filing for an IPO of $86.25 million.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription